Qilu Pharmaceutical Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: WX-0593 Tablets
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 176
- Registration Number
- NCT04641754
- Locations
- 🇨🇳
Thoracic Oncology I Department, Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Oncology Department, Anhui Cancer Hospital, Hefei, Anhui, China
Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: WX-0593 Tablets
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 292
- Registration Number
- NCT04632758
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 517
- Registration Number
- NCT04629846
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
🇨🇳Tianjin Medical University Cancer Institution & Hospital, Tianjin, Tianjin, China
To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 700
- Registration Number
- NCT04550949
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Sun Yat-sen University Cancer Hospital, Guangzhou, Guangdong, China
A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.
- Conditions
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 492
- Registration Number
- NCT04435652
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 86
- Registration Number
- NCT04326829
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
🇨🇳Fudan University Cancer Hospital, Shanghai, Shanghai, China
A Study of QL1706 in Subjects With Advanced Malignant Tumor
- Conditions
- Advanced Malignant Tumor
- Interventions
- Biological: QL1706
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 99
- Registration Number
- NCT04296994
- Locations
- 🇨🇳
Sun Yat-sen Univeisity Cancer Center, Guangzhou, Guangdong, China
Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 94
- Registration Number
- NCT04234594
- Locations
- 🇨🇳
Guizhou Cancer Hospital, Guiyang, Guizhou, China
🇨🇳First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 590
- Registration Number
- NCT04233151
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults
- First Posted Date
- 2019-12-30
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT04213105
- Locations
- 🇨🇳
The First Affiliated Hospital of Jilin University, Changchun, Jilin, China